A Phase 1, Double-Blind, Randomized, Placebo-controlled, Single Ascending Dose Study of Flecainide Acetate Inhalation Solution to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

Trial Profile

A Phase 1, Double-Blind, Randomized, Placebo-controlled, Single Ascending Dose Study of Flecainide Acetate Inhalation Solution to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Flecainide (Primary) ; Flecainide
  • Indications Paroxysmal atrial fibrillation
  • Focus Adverse reactions
  • Sponsors InCarda Therapeutics
  • Most Recent Events

    • 14 Aug 2017 Status changed from recruiting to completed.
    • 07 Jun 2017 Results published in an InCarda Therapeutics media release.
    • 31 Aug 2016 According to InCarda Therapeutics media release, this study is being conducted at CMAX, a division of IDT Australia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top